Drug Trial Radar · NCT03315455
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
Last checked: Nov 20, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
85
Actual
Start
Apr 26, 2018
Primary completion
Aug 3, 2022
Study completion Aug 29, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Oct 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, open-label, Phase 3 study with randomized and non-randomized arms is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII (FVIII) inhibitor status. Participants greater than or equal to (≥)12 years old who received episodic therapy with FVIII or bypassing agents prior to study entry and experienced at least 5 bleeds over the prior 24 weeks will be randomized in a 2:2:1 ratio to the following regimens: Arm A: Emicizumab prophylaxis at 3 milligrams per kilogram (mg/kg) once every week (QW) subcutaneously (SC) for 4 weeks, followed by 1.5 mg/kg QW SC; Arm B: Emicizumab prophylaxis at 3 mg/kg QW SC for 4 weeks, followed by 6 mg/kg once every 4 weeks (Q4W) SC; and Arm C: No prophylaxis (control arm). In addition, pediatric participants less than (\<)12 years old with hemophilia A and FVIII inhibitors who received episodic therapy with bypassing agents prior to study entry will be enrolled to Arm D: Emicizumab prophylaxis at 3 mg/kg QW SC for 4 weeks, followed by 1.5 mg/kg QW SC.
Conditions
- Hemophilia A
Interventions
EmicizumabDrug
Emicizumab will be administered via subcutaneous (SC) injection, as described for each treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Model-Based Annualized Bleeding Rate for Treated BleedsTime frame: From Baseline to at least 24 weeks
- Mean Calculated Annualized Bleeding Rate for Treated BleedsTime frame: From Baseline to at least 24 weeks
- Median Calculated Annualized Bleeding Rate for Treated BleedsTime frame: From Baseline to at least 24 weeks
Locations
13 sites in 4 countries. Site status is shown where the registry gives one.
Beijing Children's Hospital, Capital Medical University
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Xiangya Hospital of Centre-South University
Changsha, China
Southern Medical University Nanfang Hospital
Guangdong Province Guangzhou City, China
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, China
Tianjin Institute of Hematology & Blood Diseases Hospital
Tianjin, China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, China
Queen Mary Hospital
Hong Kong, Hong Kong
Prince of Wales Hospital
Shatin, Hong Kong
Penang General Hospital
George Town, Pulau Pinang, Malaysia
Queen Elizabeth Hospital
Sabah, Sabah, Malaysia
Ramathibodi Hospital
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.